Search Results

Deals

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - June 28, 2024

Nevro Corp. announced that on June 7, 2024, the Compensation Committee of the Company’s Board of Directors granted inducement restricted stock unit awards covering 56,692 shares of Nevro’s common stock to 17 new non-executive employees to induce them to accept employment with Nevro.

June 28, 2024

·

2 min read

Biotech Bay

Nevro to Present at Truist Securities MedTech Conference

Nevro Corp. announced that members of its management team will participate in a “fireside chat” session at the Truist Securities MedTech Conference on Tuesday, June 18, 2024, beginning at approximately 8:40 am EDT.

June 11, 2024

·

2 min read

Biotech Bay

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Nevro Corp. announced that on May 7, 2024, the Compensation Committee of the Company’s Board of Directors granted inducement restricted stock unit awards covering 59,460 shares of Nevro’s common stock to twenty-six new non-executive employees to induce them to accept employment with Nevro.

May 24, 2024

·

2 min read

Business

Nevro Reports First-Quarter 2024 Financial Results

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results.

May 7, 2024

·

19 min read

Biotech Bay

Nevro to Present at BofA Securities 2024 Healthcare Conference

Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that members of its management team will participate in the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, 2024.

May 9, 2024

·

2 min read

Press Releases

Nevro Reports Third-Quarter 2024 Financial Results

November 12, 2024

·

18 min read

Business

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024

Nevro Corp. today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024.

April 17, 2024

·

2 min read

Business

Nevro Enters Into Cooperation Agreement With Engaged Capital

Nevro Corp. announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC, pursuant to which Kirt P. Karros has been appointed to Nevro’s Board of Directors as well as the Audit Committee of the Board effective February 20, 2024.

February 21, 2024

·

4 min read

Biotech Bay

Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw

Nevro Corp. (NYSE: NVRO) today announced that the U.S. Food and Drug Administration (FDA) cleared its sacroiliac joint fusion device, which will be marketed as Nevro1, without the need to include the screw (“NevroFix™").

February 28, 2024

·

3 min read

Business

Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results.

February 21, 2024

·

19 min read